

LITERATUR

1. *Azuara-Blanco A et al (2016)* Effectiveness of early lens extraction for the treatment of angle-closure glaucoma (EAGLE): a randomized controlled trial. *Lancet* 388: 1389–1397
2. *Bengtsson B et al (2007)* Fluctuations of intraocular pressure and glaucoma progression in the Early Manifest Glaucoma Trial. *Ophthalmology* 114: 205–209
3. *Bengtsson B et al (2018)* The Glaucoma Intensive Treatment Study (GITS), a randomized clinical trial: design, methodology and baseline data. *Acta Ophthalmol* 96: 557–566
4. *Brandt JD et al (2001)* Central corneal thickness in the Ocular Hypertension Treatment Study. *Ophthalmology* 108: 1779–1788
5. *Budenz DL et al (2006)* Detection and prognostic significance of optic disc hemorrhages during the Ocular Hypertension Treatment Study. *Ophthalmology* 113: 2137–2143
6. *Canadian Glaucoma Study Group (2006)* Canadian Glaucoma Study: 1. Study design, baseline characteristics, and preliminary analyses. *Can J Ophthalmol* 41: 566–575
7. *Chauhan BC et al (2008)* Canadian Glaucoma Study: 2. Risk factors for the progression of open-angle glaucoma. *Arch Ophthalmol* 126: 1030–1036
8. *Chauhan BC et al (2010)* Canadian Glaucoma Study: 3. Impact of risk factors and intraocular pressure reduction on the rates of visual field change. *Arch Ophthalmol* 128: 1249–1255
9. *Chua J et al (2015)* Prevalence, risk factors, and visual features of undiagnosed glaucoma: The Singapore Epidemiology of Eye Diseases Study. *JAMA Ophthalmol* 133: 938–946
10. *Collaborative Normal Tension Glaucoma Study Group (1998)* Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. *Am J Ophthalmol* 126: 487–497
11. *Collaborative Normal Tension Glaucoma Study Group (1998)* The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. *Am J Ophthalmol* 126: 498–506
12. *Drance SM (2004)* Some clinical implications of the Collaborative Normal Tension Glaucoma Study. *Klin Oczna* 106: 588–592
13. *Ederer F et al (1994)* The Advanced Glaucoma Intervention Study: 1. Study design and methods and baseline characteristics of study patients. *Control Clin Trials* 15: 299–325
14. *Founti P et al (2018)* Overdiagnosis of open-angle glaucoma in the general population: the Thessaloniki Eye Study. *Acta Ophthalmol* 96: e859–e864
15. *Garway-Heath DF et al (2013)* The United Kingdom Glaucoma Treatment Study: a multicenter, randomized, placebo-controlled clinical trial: design and methodology. *Ophthalmology* 120: 68–76
16. *Garway-Heath DF et al (2014)* Latanoprost for open-angle glaucoma (UKGTS): a randomized, multicentre, placebo-controlled trial. *Lancet online doi.org/10.1016/S0140-6736(14)62111-5*
17. *Gazzard G et al (2019)* Selective laser trabeculoplasty versus eye drops for first-line treatment of ocular hypertension and glaucoma (LiGHT): a multicentre randomised controlled trial. *Lancet online doi.org/10.1016/S0140-6736(18)32213-X*
18. *Gordon MO, Kass MA (1999)* The Ocular Hypertension Treatment Study: design and baseline description of the participants. *Arch Ophthalmol* 117: 573–583
19. *Gordon MO et al (2002)* The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma. *Arch Ophthalmol* 120: 714–720
20. *Gordon MO, Kass MA (2018)* What we have learned from the Ocular Hypertension Treatment Study. *Am J Ophthalmol* 189: 24–27
21. *He M et al (2019)* Laser peripheral iridotomy for the prevention of angle closure: a single-centre, randomized controlled trial. *Lancet online doi.org/10.1016/S0140-6736(18)32607-2*
22. *Hyman L et al (2010)* Natural history of intraocular pressure in the Early Manifest Glaucoma Trial: A 6-year follow-up. *Arch Ophthalmol* 128: 601–607
23. *Jiang Y et al (2010)* Design and methodology of a randomized controlled trial of laser iridotomy for the prevention of angle closure in southern China: The Zhongshan Angle-Closure prevention Trial. *Ophthalmic Epidemiol* 17: 321–332
24. *Jiang Y et al (2014)* Longitudinal changes of angle configuration in primary angle-closure suspects: The Zhongshan Angle-Closure prevention Trial. *Ophthalmology* 121: 1699–1705
25. *Kass MA et al (2010)* Delaying treatment of ocular hypertension: Ocular Hypertension Treatment Study. *Arch Ophthalmol* 128: 276–287
26. *Keltner JL et al (2000)* Confirmation of visual field abnormalities in the Ocular Hypertension Treatment Study. *Arch Ophthalmol* 118: 1187–1194
27. *Krupin T et al (2011)* A randomized trial of Brimonidin versus Timolol in preserving visual function: Results from the Low-pressure Glaucoma Treatment Study. *Am J Ophthalmol* 151: 671–681
28. *Law A et al (2017)* Missed opportunity from randomized controlled trials of medical interventions for open-angle glaucoma. *Br J Ophthalmol* 101: 1315–1317
29. *Leske MC et al (1999)* Early Manifest Glaucoma Trial: design and baseline data. *Ophthalmology* 106: 2144–2153
30. *Leske MC et al (2003)* Factors for glaucoma progression and the effect of treatment: The Early Manifest Glaucoma Trial. *Arch Ophthalmol* 121: 48–56
31. *Leske MC et al (2007)* Predictors of long-term progression in the Early Manifest Glaucoma Trial. *Ophthalmology* 114: 1965–1972
32. *Lichter PR et al (2001)* Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. *Ophthalmology* 108: 1943–1953
33. *Linden C et al (2018)* Initial intraocular pressure reduction by mono- versus multi-therapy in patients with open-angle glaucoma: results from the Glaucoma Intensive Treatment Study. *Acta Ophthalmol* 96: 567–572
34. *Malik R et al (2016)* Canadian Glaucoma Study: 4. Neuroretinal rim area change in glaucoma patients with visual field progression endpoints and intraocular pressure reduction. *Am J Ophthalmol* 163: 140–147
35. *Miglior S et al (2002)* The European Glaucoma Prevention Study: design and baseline description of the participants. *Ophthalmology* 109: 1612–1621
36. *Miglior S et al (2005)* The results of the European Glaucoma Prevention Study. *Ophthalmology* 112: 366–375
37. *Miglior S et al (2007)* Predictive factors for open-angle glaucoma among patients with ocular hypertension in the European Glaucoma Prevention Study. *Ophthalmology* 114: 3–9
38. *Musch DC et al (1999)* The Collaborative Initial Glaucoma Treatment Study: study design, methods, and baseline characteristics of enrolled patients. *Ophthalmology* 106: 653–662
39. *Musch DC et al (2006)* Cataract extraction in the Collaborative Initial Glaucoma Treatment Study: incidence, risk factors, and the effect of cataract progression and extraction on clinical and quality-of-life outcomes. *Arch Ophthalmol* 124: 1694–1700
40. *Musch DC et al (2011)* Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. *Ophthalmology* 118: 1766–1773
41. *Peters D et al (2015)* Visual impairment and vision-related quality of life in the Early Manifest Glaucoma Trial after 20 years of follow-up. *Arch Ophthalmol* 93: 745–752

42. *Schulzer M (1992)* Intraocular pressure reduction in normal-tension glaucoma patients. The Normal Tension Glaucoma Study Group. *Ophthalmology* 1999: 1468–1470
43. *The AGIS Investigators (1998)* The Advanced Glaucoma Intervention Study: 4. Comparisons of treatment outcomes within race. Seven-year results. *Ophthalmology* 105: 1146–1164
44. *The AGIS Investigators (2000)* The Advanced Glaucoma Intervention Study: 7. The relationship between control of intraocular pressure and visual field deterioration. *Am J Ophthalmol* 130: 429–440
45. *The AGIS Investigators (2001)* The Advanced Glaucoma Intervention Study: 8. Risk of cataract formation after trabeculectomy. *Arch Ophthalmol* 119: 1771–1779
46. *The AGIS Investigators (2002)* The Advanced Glaucoma Intervention Study: 11. Risk factors for failure of trabeculectomy and argon laser trabeculectomy. *Am J Ophthalmol* 134: 481–498
47. *Topouzis F et al (2007)* Prevalence of open-angle glaucoma in Greece: The Thessaloniki Eye Study. *Am J Ophthalmol* 144: 511–519
48. *Topouzis F et al (2011)* Risk factors for primary open-angle glaucoma and pseudoexfoliative glaucoma in the Thessaloniki Eye Study. *Am J Ophthalmol* 152: 219–228
49. *Tham YC et al (2016)* Joint effects of intraocular pressure and myopia on risk of primary open-angle glaucoma: The Singapore Epidemiology of Eye Diseases Study. *Sci Rep* 6: 19320
50. *Weinreb RN et al (2018)* Oral Memantine for the treatment of glaucoma. Design and results of 2 randomized, placebo-controlled, Phase 3 studies. *Ophthalmology* 125: 1874–1885
51. *Zahid S et al (2013)* Risk of endophthalmitis and other long-term complications in the Collaborative Initial Glaucoma Treatment Study. *Am J Ophthalmol* 155: 647–680